• Unmet Need

TRODELVY 200mg

Unmet Need

TRODELVY is indicated for use as early as 2L mTNBC1

Current treatment choises for 2L mTNBC

mTNBC remains the most difficult-to-treat breast cancer subtype4

Patients with mTNBC are lost with each line of treatment5

For patients with mTNBC, survival and quality of life are the two most important aspects of treatment6

There is a significant need for more efficacious and tolerable treatment options in mTNBC7

ABBREVIATIONS:

1L, first line; 2L, second line; 3L, third line; 4L, fourth line; ESMO, European Society for Medical Oncology; mTNBC, metastatic triple-negative breast cancer; TNBC, triple-negative breast cancer; CI, confidence interval; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; mut, mutant; OS, overall survival.

REFERENCES:

  1. TRODELVY (sacituzumab govitecan) Summary of Product Characteristics. July 2023.
  2. Gennari A, et al. Ann Oncol. 2021;32(12):1475–1495.
  3. Fangyuan, et al. Oncotarget. 2017;8(42):73329–73344.
  4. Seah DS, et al. J Natl Compr Canc Netw. 2014;12(1):71–80.
  5. Kantar Health CancerMPact. Accessed: March 2021.
  6. Canadian Agency for Drugs and Technologies (CADTH). Available at: https://www.cadth.ca/sites/default/files/attachments/2021-08/Sacituzumab%20govitecan%20-%20Patient%20Group%20Input%20-%20For%20posting.pdf. Accessed: April 2022.
  7. Lehmann BD, et al. J Clin Invest. 2011;121(7):2750–2767.
  8. Abramson VG, et al. Cancer. 2015;121(1):8–16.
  9. O’Reilly D, et al. World J Clin Oncol. 2021;12(3):164–182.